Physician profile
Robert Yuhas
NPI 1700897642
$6,204.76
in general payments reported to CMS, 2019-2025
51 companies · $300 in 2025
The $300 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,353 · 2020: $720 · 2021: $1,176 · 2022: $1,321 · 2023: $936 · 2024: $398 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,633.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $807.94 | 2019-2025 | Repatha, Evenity, Otezla |
| Glaxosmithkline, LLC. | $806.52 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Philips North America LLC | $482.92 | 2019-2024 | (Ck7) Extended Holter |
| Astrazeneca Pharmaceuticals Lp | $320.91 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $314.92 | 2019-2025 | Mounjaro, Kisunla |
| Radius Health, INC. | $306.38 | 2022 | |
| Novartis Pharmaceuticals Corporation | $290.67 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $289.33 | 2022-2023 | |
| Pfizer INC. | $208.26 | 2019-2022 | |
| Amarin Pharma, INC. | $205.96 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $169.66 | 2019-2021 | |
| Eisai INC. | $162.43 | 2021 | |
| Janssen Pharmaceuticals, INC | $143.49 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $135.10 | 2019 | |
| Exact Sciences Corporation | $129.85 | 2023-2025 | Cologuard Collection Kit |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Yuhas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.